China Pegylated Drugs Market

ID: MRFR/Pharma/48031-HCR
200 Pages
Nidhi Mandole
Last Updated: April 06, 2026
China Pegylated Drugs Market Research Report By Molecule (Protein, FAB’ Fragment, Enzyme, Aptamer) and By Indication (Cancer, Gout, Hemophilia, Hepatitis) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

China Pegylated Drugs Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)5.12%
2024 Market Size$ 1,138.5 Million
2025 Market Size$ 1,196.79 Million
2035 Market Size$ 1,971 Million

Key Players

Amgen
Roche
Merck & Co
Bristol-Myers Squibb
Pfizer
Novartis
Opportunities
  • Growing Aging Population
  • Increased Healthcare Expenditure
  • Regulatory Framework Enhancements
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Food, Beverages & Nutrition, BY Molecule (USD Million)
      1. 4.1.1 Macromolecular Drugs
      2. 4.1.2 Small Molecular Drugs
      3. 4.1.3 Lipid Nanoparticles (LNP)
      4. 4.1.4 Liposomes
    2. 4.2 Food, Beverages & Nutrition, BY Application (USD Million)
      1. 4.2.1 Oncology
      2. 4.2.2 Neurology
      3. 4.2.3 Autoimmune Diseases
      4. 4.2.4 Rare Haematology
      5. 4.2.5 Others
    3. 4.3 Food, Beverages & Nutrition, BY Distribution Channel (USD Million)
      1. 4.3.1 Hospital Pharmacy
      2. 4.3.2 Online Pharmacy
      3. 4.3.3 Retail Pharmacy
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Amgen (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Roche (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Merck & Co (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Bristol-Myers Squibb (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Pfizer (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Novartis (CH)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Eli Lilly and Company (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 AstraZeneca (GB)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 CHINA MARKET ANALYSIS BY MOLECULE
    3. 6.3 CHINA MARKET ANALYSIS BY APPLICATION
    4. 6.4 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    5. 6.5 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
    8. 6.8 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    10. 6.10 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
    11. 6.11 FOOD, BEVERAGES & NUTRITION, BY MOLECULE, 2024 (% SHARE)
    12. 6.12 FOOD, BEVERAGES & NUTRITION, BY MOLECULE, 2024 TO 2035 (USD Million)
    13. 6.13 FOOD, BEVERAGES & NUTRITION, BY APPLICATION, 2024 (% SHARE)
    14. 6.14 FOOD, BEVERAGES & NUTRITION, BY APPLICATION, 2024 TO 2035 (USD Million)
    15. 6.15 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    16. 6.16 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY MOLECULE, 2025-2035 (USD Million)
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
      3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

China Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Molecule (USD Million, 2025-2035)

  • Macromolecular Drugs
  • Small Molecular Drugs
  • Lipid Nanoparticles (LNP)
  • Liposomes

Food, Beverages & Nutrition By Application (USD Million, 2025-2035)

  • Oncology
  • Neurology
  • Autoimmune Diseases
  • Rare Haematology
  • Others

Food, Beverages & Nutrition By Distribution Channel (USD Million, 2025-2035)

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy